43 patients received hematopoietic stem cell transplantation (HSCT) in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival of 56.8% and overall survival of 80.2% were accomplished.
[Blood Advances]
7992332
{7992332:BBBBBBBB}
apa
50
1
167863
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
